Market Highlights:
Orthobiologics, also called regenerative cellular therapies, is an advancing medical field that involves the use of biomaterials and cell-based therapies to repair broken bones, prevent bone degeneration, and provide bone stability. Orthobiologic products are obtained from naturally occurring materials. These products help treat people with long-term disabling musculoskeletal disorders and injuries. In the current scenario, emerging technological innovations in biomaterials, used in the production of orthobiologics are emerging out as a lucrative opportunity for the market growth The market study is being classified by Type (Viscosupplementation Products, DBM, Synthetic Orthobiologics, BMP, Allografts, PRP and BMAC), by Application (Fracture Recovery, Spinal Fusion, Soft Tissue Injuries and Osteoarthritis and Degenerative Arthritis) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Key Players:
The prominent players in the Orthobiologics are DePuy Synthes (Johnson & Johnson) (United States), Medtronic (Ireland), Sanofi S.A (France), Stryker (United States), Zimmer Biomet (United States), Alphatec Spine Inc. (United States), AlloSource (United States), SINTX Technologies Inc. (United States), Anika Therapeutics (United States), Arthrex Inc. (United States), Baxter (United States), BBS-Bioactive Bone Substitutes (Finland), Berkeley Advanced Biomaterial (United States), Wright Medical Group Inc. (United States), Bioventus (United States), Bone Therapeutics (Belgium), Ceramisys (United Kingdom) and Geistlich Bio-Oss (United States).

The End User, such as Hospitals, is boosting the Orthobiologics market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

Major Market Development Highlights
In February 2019, Orthofix Medical Inc., a global medical device company focused on musculoskeletal products and therapies, announced that it has acquired the business of Options Medical, LLC, a medical device distributor based in Florida
In March 2019, AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, announced that it has enrolled the first patient in a study titled A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee. and In January 2019, Bioventus, launched OSTEOMATRIX+, next-generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications

Key Questions Answered in the Report
What will the Orthobiologics Market size and the growth rate be in Future?
What are the key factors driving the Orthobiologics Market?
What are the key market trends and macro-economic impacting the growth of the Orthobiologics Market?
What are the challenges to market growth?
Who are the key vendors in the Orthobiologics Market?
What are the market opportunities and threats faced by the vendors in the Orthobiologics Market?
Trending factors influencing the market shares of the Players.
What are the key outcomes of the five forces analysis of the Orthobiologics Market?

Refer complete Table of Content of Orthobiologics Market Study

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Orthobiologics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Orthobiologics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Orthobiologics Product Manufacturing Companies, Product Suppliers, Distributors, and Channel Partners, Hospitals and Ambulatory Care Centers, Orthopedic and Dental Clinics, Research Laboratories and CROs, Research and Academic Institutes, National and International Regulatory Authorities and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.